All candidates for NAD+ therapy should be screened by a qualified provider to ensure no individualized contraindications or safety concerns
Poster Session II - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.01 - REHABILITATION P832 - ESOC25-1295 POST-STROKE FACIAL PALSY: PREVALENCE ON ADMISSION, RISK FACTORS, AND RECOVERY WITH HYPER-ACUTE TREATMENTS Zewen Lu 1 , Havva Eroglu 2 , Halvor Nss 3 , Matthew Gittins 1 , Amit Kishore 4 , Craig Smith 5 , Andy Vail 1 , Claire Mitchell 2 1 Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2 Division of Psychology, Communication & Human Neuroscience, Geoffrey Jefferson Brain Research Centre, University of Manchester, Manchester, United Kingdom, 3 Department of Neurology, University of Bergen, Haukeland University Hospital, Bergen, Norway, 4 Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, 5 Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, Manchester, United Kingdom Background and Aims: Facial palsy affects 40 - 50% of stroke survivors, impacting quality of life, communication, and emotional expression
The trial uses a CAR-T editing strategy made to target CD19, which the company is also testing for a cancer therapy
See the CMS CY 2026 Physician Fee Schedule Final Rule, October 31, 2025 for the complete authoritative source
